FDA Approvals

FDA alerts customers to voluntary recall of compounded drugs due to sterility issues by Drug Depot, LLC, dba APS Pharmacy

FDA1d ago1 min read

FDA is alerting patients, health care professionals, veterinarians, and animal owners/caretakers about a voluntary recall by Drug Depot, LLC, doing business as APS Pharmacy, of certain unexpired compounded drugs due to a lack of sterility assurance.

Read full article on FDA

AI Summary

Quick Take

Drug Depot, LLC, doing business as APS Pharmacy, has issued a voluntary recall of certain unexpired compounded drugs intended to be sterile due to a lack of sterility assurance. The FDA alert affects medications for both human and veterinary use, posing a potential risk of serious infection to patients.

Why It Matters

Sterility is non-negotiable for ophthalmic medications, whether they are injectables or topical drops, as contaminated products can lead to sight-threatening infections like endophthalmitis. This recall highlights the ongoing regulatory scrutiny of compounding pharmacies and the risks associated with sourcing medications from facilities that may have compromised aseptic processing. For eye care providers, this is a critical safety alert that requires immediate inventory checks to prevent patient harm.

Key Details

The recall was initiated voluntarily by Drug Depot, LLC (dba APS Pharmacy) following concerns over sterility assurance.
The action involves certain unexpired compounded drugs that were intended to be sterile.
The FDA alert is directed at healthcare professionals, patients, and veterinarians, as the pharmacy produces both human and animal medications.
A lack of sterility assurance indicates that the products may have been exposed to contamination during the compounding process.

Practice Implications

Clinicians should immediately identify any sterile compounded medications in their inventory sourced from APS Pharmacy and quarantine them. Patients who have received these medications should be notified to discontinue use and should be closely monitored for any signs of ocular infection or adverse reactions.

Who's Affected

OphthalmologistsOptometristsVeterinary OphthalmologistsPractice OwnersPharmacy Staff

What's Next

The FDA will continue to monitor the recall and the pharmacy's corrective actions. Providers should transition patients to alternative sterile sources or commercially available equivalents where possible to ensure continuity of care.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.